Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven ...

Ovid’s playful poetry made him a favorite among Rome’s elite, but angered Emperor Augustus. Just as he was producing his finest work, Ovid (43 BC – 17 AD) was exiled to the darkest corner of ...

Barclays PLC raised its holdings in Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) by 311.2% during the third quarter, according to its most recent filing with the Securities and Exchange ...

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by ...